Transcatheter closure of both symptomatic atrial septal defect (ASD) and patent foramen ovale (PFO) has become a standard procedure in daily clinical practice, guaranteeing excellent technical results in terms of efficacy and safety. Although indications to closure are different between ASD and PFO, device type and shape are constructively very similar and in some case even identical between ASD and PFO populations [1]: as result, any proposed antiplatelet therapy was irrespective to the defect type and the two population can be analysed as a single one for pharmacologic purposes.
